Drugs / ABBV-400
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06084481 | Nov 2023 → Jul 2026 overdue | biliary tract cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, hepatocellular carcinoma +3 | AbbVie | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06107413 | Nov 2023 → Dec 2026 expected | colorectal cancer | AbbVie | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-400 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06084481 ↗ |
| Route | Intravenous | “Intravenous (IV) Infusion” NCT06084481 ↗ |